CTS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CTS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $541.32M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $514.76M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $550.42M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $586.87M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $512.93M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $123.02M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $113.78M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $84.20M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $103.08M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $115.04M | Feb 25, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.03M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $187.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $190.86M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $210.54M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $184.62M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $42.69M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $36.91M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $26.57M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $32.90M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $38.70M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.32M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $55.47M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $60.53M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $59.58M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($41.87M) | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $14.95M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $11.07M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $4.86M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $3.81M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $10.06M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.64M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $71.19M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $75.05M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $93.01M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $76.48M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $17.14M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $13.26M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $6.24M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $8.49M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $12.39M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.27M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $23.39M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $24.92M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $24.10M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $23.86M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $24.32M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $25.97M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $25.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $25.15M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $24.04M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.72M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $88.29M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $83.82M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $91.52M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $82.60M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $67.79M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $70.41M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $73.57M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $71.94M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $61.62M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.11M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $98.24M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $88.81M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $121.20M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $86.14M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $76.78M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $64.41M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $58.15M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $58.05M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $47.20M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $764.31M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $765.43M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $741.17M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $748.49M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $664.46M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $626.05M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $643.35M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $548.34M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $539.70M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $517.70M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.53M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $237.22M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $214.35M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $242.26M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $200.88M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $202.37M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $238.14M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $170.41M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $195.89M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $199.82M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $551.79M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $528.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $526.82M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $506.22M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $463.58M | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $423.68M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $405.22M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $377.93M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $343.81M | Feb 25, 2021 |
| FY2017 | Dec 31, 2016 | $317.88M | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.61M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $201.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $157.64M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $152.36M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $109.80M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $109.50M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $106.06M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $71.06M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $71.06M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $61.74M | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.47M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $652.85M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $602.23M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $546.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $492.24M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $539.28M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $509.77M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $478.85M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $420.16M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $410.98M | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $94.33M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $163.88M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $156.91M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $141.47M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $91.77M | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $100.24M | Feb 25, 2022 |
| FY2021 | Dec 31, 2018 | $100.93M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $113.57M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $113.81M | Feb 20, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $75.00M | Mar 3, 2014 |
| FY2012 | Dec 31, 2012 | $153.50M | Feb 25, 2013 |
| FY2012 | Dec 31, 2011 | $74.40M | Feb 25, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.76M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 30.03M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 30.82M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 31.68M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 32.18M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 32.28M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | 32.47M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 32.75M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | 32.94M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | 32.76M | Feb 22, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.75M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.89M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $5.04M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.13M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $5.17M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $5.18M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $5.24M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $5.29M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $5.26M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $5.23M | Feb 22, 2019 |